Chiesi acquires majority stake in Cornerstone in exchange for Curosurf
This article was originally published in Scrip
Executive Summary
Cornerstone Therapeutics, a US-based pharmaceutical company, is to buy an exclusive 10-year licence for the US commercial rights to Chiesi Farmaceutici's Curosurf, which is used to treat respiratory distress syndrome (RDS) in premature infants.